What Is Rosuvastatin Calcium? Uses and Side Effects

Rosuvastatin calcium is a prescription cholesterol-lowering medication belonging to the statin family. Sold under the brand name Crestor and now widely available as a generic, it works by blocking a liver enzyme involved in cholesterol production, and it is one of the most potent statins on the market. At standard doses of 10 to 40 mg per day, it can reduce LDL (“bad”) cholesterol by roughly 46% to 55%, and it has been studied extensively for both treating high cholesterol and preventing heart attacks and strokes in people who have never had one.

How Rosuvastatin Works

Your liver manufactures most of the cholesterol circulating in your blood. The key bottleneck in that production line is an enzyme called HMG-CoA reductase. Rosuvastatin is a fully synthetic compound designed to block that enzyme, slowing the liver’s cholesterol output.¹ When cholesterol production drops inside liver cells, those cells respond by pulling more LDL cholesterol out of the bloodstream to compensate, which is what actually drives your blood levels down.

One feature that distinguishes rosuvastatin from several other statins is that it is hydrophilic, meaning it dissolves more readily in water than in fat. This gives it greater selectivity for the liver, because it gets actively transported into liver cells rather than passively drifting into other tissues.² That liver selectivity is part of why rosuvastatin is effective at relatively low doses and may partly explain its side-effect profile compared to fat-soluble (lipophilic) statins like atorvastatin or simvastatin.

Cholesterol-Lowering Power

Rosuvastatin is among the strongest statins available for lowering LDL cholesterol. A large Cochrane review combining data from over 19,500 participants across 108 trials found that doses of 10 to 40 mg per day lowered LDL by about 46% to 55%, with a strong and consistent dose-response relationship for total cholesterol, LDL, and non-HDL cholesterol.³ The review also found that rosuvastatin raised HDL (“good”) cholesterol by about 7% on average, though that increase did not change much with higher doses.

Earlier dose-ranging research showed that even very low doses have a measurable effect: a 1 mg dose reduced LDL by about 34%, while 80 mg brought it down by roughly 65%. Each doubling of the dose added about another 4.5 percentage points of LDL reduction.⁴ In practice, most people are prescribed between 5 mg and 40 mg daily, with 20 mg and 40 mg considered “high-intensity” statin therapy under current guidelines.

How It Stacks Up Against Other Statins

In head-to-head comparisons, rosuvastatin consistently edges out atorvastatin for raw LDL reduction. In the URANUS trial, which enrolled people with type 2 diabetes, rosuvastatin lowered LDL by 52% compared with 46% for atorvastatin, and 75% of patients hit their LDL target on the starting dose of rosuvastatin versus 54% on the starting dose of atorvastatin.⁵ A more recent systematic review and meta-analysis comparing the two drugs at their highest approved doses confirmed that rosuvastatin 40 mg was statistically more effective at reducing LDL than atorvastatin 80 mg.⁶

That said, atorvastatin remains the most widely prescribed statin worldwide, partly because it has been generic for longer and partly because its clinical-outcomes data are enormous. The LDL advantage of rosuvastatin is real but modest, and whether those extra percentage points translate into meaningfully fewer heart attacks at a population level is a harder question to answer. Both drugs are considered high-intensity statins, and guidelines generally treat them as largely interchangeable for most patients.

Preventing Heart Attacks and Strokes

The landmark trial for rosuvastatin in cardiovascular prevention is JUPITER, which enrolled nearly 18,000 apparently healthy people who had normal LDL cholesterol but elevated levels of C-reactive protein, a marker of inflammation. After a median follow-up of less than two years, the trial was stopped early because the rosuvastatin group was doing so much better. Rates of heart attack were cut by roughly half, stroke by about half, and the combined endpoint of heart attack, stroke, or cardiovascular death dropped by close to 47%. Even death from any cause fell by about 20%.⁷

Those benefits held up across different risk levels and demographic groups. A post-hoc analysis focusing on people at the highest cardiovascular risk found similarly large reductions in events, with rates of heart attack, stroke, and cardiovascular death roughly halved in the rosuvastatin group.⁸ Separate analyses confirmed the drug worked in both white and non-white participants.⁹

Beyond preventing events, rosuvastatin has been shown to physically shrink the fatty plaques inside coronary arteries. Imaging studies using intravascular ultrasound in patients with stable coronary artery disease found significant plaque regression, with one Japanese study showing roughly a 5% reduction in plaque volume after treatment.¹⁰ Higher doses appear to be more effective at this: a randomized trial comparing high-dose and low-dose rosuvastatin found that both stabilized plaques, but only the higher dose produced significant volume regression.¹¹

Common Side Effects

The side effects people worry about most with any statin are muscle problems. Symptoms range from soreness and cramping to fatigue and weakness, and they tend to show up in large muscle groups like the thighs, calves, back, and buttocks.¹² These complaints are relatively common across all statins and can become more noticeable during or after strenuous exercise.¹³ In rare cases, statins can cause a severe form of muscle breakdown called rhabdomyolysis, which requires immediate medical attention. The risk is low, but it’s the reason doctors monitor for unexplained muscle pain.

Liver effects are another consideration. Rosuvastatin is taken up by liver cells more selectively and efficiently than some other statins, and while serious liver damage is rare, case reports of clinically significant liver toxicity have been documented even at standard doses.¹⁴ Routine liver function tests are no longer universally required before starting a statin, but your doctor will typically check them at least once early on and again if symptoms develop.

The Diabetes Question

One side effect that gets a lot of attention is the link between statin use and new-onset diabetes. This is a real effect, not a myth, and rosuvastatin is no exception. Research has found that the drug has a dual effect on blood sugar: it improves insulin sensitivity (a good thing) but simultaneously impairs the ability of insulin-producing cells in the pancreas to secrete insulin properly.¹⁵ The net result, especially in people who are already at risk for diabetes, can tip blood sugar in the wrong direction.

A clinical study in Japanese patients with type 2 diabetes found that switching to even a low dose of rosuvastatin worsened glucose control, particularly in those whose fasting blood sugar was already elevated.¹⁶ For most people, the cardiovascular benefits of the drug far outweigh the modest diabetes risk, but if you are already borderline diabetic, it is something worth discussing with your doctor and monitoring periodically.

Drug Interactions Worth Knowing About

Rosuvastatin does not rely heavily on the same liver enzymes (particularly CYP3A4) that metabolize many other drugs, which spares it from some of the interaction problems that plague simvastatin and lovastatin. Instead, its absorption and clearance depend largely on transporter proteins that shuttle it into and out of cells. When another drug blocks those transporters, rosuvastatin levels in the blood can spike.

The most dramatic examples come from cyclosporine, an immune-suppressing drug used after organ transplants, and rifampin, an antibiotic used for tuberculosis. Modeling studies predict that cyclosporine can increase rosuvastatin exposure by roughly fivefold, and rifampin by about six- to sevenfold, primarily by blocking the liver’s uptake transporters.¹⁷ Gemfibrozil, a fibrate drug sometimes used alongside statins for severe lipid problems, has a more moderate effect, roughly doubling rosuvastatin exposure.¹⁸ Certain blood pressure medications like telmisartan can also raise rosuvastatin levels through the same transporter pathway in the gut.¹⁹

The practical takeaway is simple: always tell your prescriber about every medication you take, including over-the-counter drugs and supplements. Rosuvastatin’s interaction profile is generally more favorable than some older statins, but the drugs that do interact with it can raise blood levels enough to increase the risk of muscle damage and other side effects.

Dosing Considerations for Different Populations

Not everyone handles rosuvastatin identically. One well-documented difference involves people of Asian descent, who on average reach about twice the blood levels of rosuvastatin compared to white patients at the same dose. For years, this was attributed broadly to race, and FDA labeling recommends a lower starting dose (5 mg) for Asian patients. But research has pinpointed the real culprit: genetic variation in drug transporter proteins. A prospective study comparing Asian and white volunteers who shared the same transporter gene variants found virtually identical rosuvastatin levels, eliminating the ethnic gap.²⁰

This is a meaningful distinction. A genetic variant called Q141K in the BCRP transporter, which reduces the body’s ability to clear rosuvastatin, is especially common in certain Asian subgroups like Filipinos. Researchers have argued that dosing should shift from race-based assumptions to actual genotype testing, since the variation within Asian populations is substantial.²¹ In practice, pharmacogenomic testing is not yet routine for statin prescribing, but the science strongly supports moving in that direction.

Kidney function is another important variable. The FDA recommends lower rosuvastatin doses for people with significantly reduced kidney filtration rates, because the drug can accumulate when the kidneys are not clearing it efficiently. Despite this, a large single-center review found that nearly half of patients with very low kidney function were prescribed doses above what the labeling recommends.²² If you have chronic kidney disease, it is worth confirming with your pharmacist or doctor that your dose accounts for your kidney function.

Anti-Inflammatory Effects Beyond Cholesterol

Rosuvastatin does more than just lower cholesterol. Researchers have identified a range of effects, sometimes called pleiotropic effects, that appear to be independent of lipid lowering. In animal models, rosuvastatin reduced the size and number of atherosclerotic lesions well beyond what cholesterol reduction alone could explain. It also suppressed inflammatory markers in artery walls and lowered circulating levels of proteins associated with inflammation.²³

These effects have been confirmed in humans as well. In people with HIV on antiretroviral therapy, who face elevated cardiovascular risk partly due to chronic inflammation, rosuvastatin reduced markers of vascular inflammation and immune activation independently of any changes in LDL cholesterol.²⁴ Separately, rosuvastatin improved small blood vessel function and nerve-related blood flow in people with type 2 diabetes, effects that may relate to something beyond pure cholesterol lowering.²⁵ These findings help explain why the JUPITER trial saw such dramatic reductions in cardiovascular events in people who didn’t even have elevated LDL to begin with; the anti-inflammatory effects appear to contribute real clinical benefit.

Options When You Cannot Tolerate a Daily Dose

Muscle pain is the most common reason people stop taking statins. If you have tried one or more statins and quit because of side effects, rosuvastatin offers an unusual advantage: its long half-life in the body means that less-frequent dosing can still produce meaningful cholesterol reductions. Studies have tested every-other-day dosing and found that the majority of previously statin-intolerant patients tolerated it well, with significant LDL reductions.²⁶

Even once-weekly dosing has shown promise. A study of patients who had abandoned other statins due to muscle pain found that taking a low dose of rosuvastatin just once a week lowered LDL meaningfully and was well tolerated.²⁷ Neither alternative dosing schedule has been proven to reduce heart attacks or strokes in a clinical trial the way daily dosing has, but for people who truly cannot take a statin every day, getting some cholesterol reduction is better than abandoning the drug class entirely.

Combining Rosuvastatin With Ezetimibe

When rosuvastatin alone doesn’t bring LDL low enough, the most common next step is adding ezetimibe, a drug that works in the intestine to block cholesterol absorption. The two drugs hit cholesterol from different angles, and the combination can produce substantially larger LDL reductions than increasing the rosuvastatin dose.

A Korean randomized trial found that combining rosuvastatin 10 mg with ezetimibe 10 mg lowered LDL by about 23% after six months, compared with about 13% for rosuvastatin 20 mg alone. The combination also got a much larger share of patients below an LDL target of 70 mg/dL: roughly 76% versus 51%.²⁸ An Egyptian study took the combination further, pairing a high dose of rosuvastatin (40 mg) with ezetimibe, and saw LDL drop by nearly 59% from baseline, with about a third of very-high-risk patients reaching an aggressive LDL target below 55 mg/dL.²⁹

The practical appeal of combination therapy is that you can use a moderate statin dose and add ezetimibe rather than pushing the statin to its highest dose. Since muscle side effects tend to increase with statin dose, this strategy may be easier to tolerate for some patients while delivering equal or better cholesterol lowering. Fixed-dose combination pills containing both rosuvastatin and ezetimibe are now available in several countries, making adherence easier.

The Cost Landscape

Rosuvastatin went off patent in the United States in 2016, and generic versions are now widely available. That has changed the economics considerably. When it was still brand-name-only, health economists analyzed whether the additional LDL-lowering power of rosuvastatin justified its premium over generic atorvastatin and simvastatin. A Swedish modeling study found that rosuvastatin 20 mg was cost-effective compared to generic simvastatin or atorvastatin 40 mg for patients at high cardiovascular risk, though the margins narrowed for patients at lower risk where the absolute benefit was smaller.³⁰ Now that rosuvastatin itself is available as a generic, the price gap between high-intensity statins has largely closed, and drug cost alone is rarely the deciding factor when choosing between rosuvastatin and atorvastatin. Insurance formulary placement, individual response, and tolerability tend to drive the decision more than sticker price.